Latest Reimbursement News

Advanced Health Intelligence Ltd (AHI) reports robust commercial progress and strategic funding moves in Q1 2025 despite ongoing ASX trading suspension and recent NASDAQ delisting. Key partnerships and technology validations position the company for a strong global scale-up.

Echo IQ has secured a strategic collaboration with the Mayo Clinic Platform and raised $17.3 million, advancing its AI-driven cardiology tools towards FDA clearance and US commercial scale.

Red Mountain Mining has partnered with Canadian exploration experts Fladgate to advance its Fry Lake Gold Project, while seeking Ontario government funding to offset exploration costs.

Cyclone Metals reports strong progress on its Iron Bear Project, highlighting a completed renewable energy power study and successful metallurgical test results that underpin its sustainable mining ambitions.

Telix Pharmaceuticals reported a robust 63% year-over-year revenue increase to $204 million in Q2 2025, launched its new prostate cancer imaging agent Gozellix in the U.S., and advanced key clinical trials despite an ongoing SEC inquiry.

Bod Science Limited reports a positive cash flow quarter driven by customer receipts, an R&D tax incentive, and proceeds from intellectual property sales, while navigating its Deed of Company Arrangement.

Solara Minerals has agreed to acquire a portfolio of seven exploration licences in Western Australia's Murchison region, positioning itself near major gold and copper mines. The deal includes immediate exploration plans and potential milestone-based share payments.

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.

Pacific Edge Limited has opened a $5 million Share Purchase Plan at $0.10 per share, conditional on shareholder approval of a prior $16.1 million Placement. The capital raise aims to extend the company’s cash runway and accelerate US market adoption of its bladder cancer diagnostic tests amid Medicare non-coverage.

ImpediMed has doubled its US unit sales in Q4 FY25, achieving a record total contract value and securing an additional $5 million tranche under its growth capital facility.

EBR Systems has received preliminary approval from the U.S. Centers for Medicare & Medicaid Services for outpatient reimbursement of its WiSE® CRT System, marking a major step toward broader hospital adoption.

INOVIQ Limited reports strong clinical validation for its EXO-OC ovarian cancer screening test and promising preclinical results for CAR-exosome therapeutics targeting aggressive cancers.